Pfizer returns asthma drug development to Rigel – Forbes

Pfizer returns asthma drug development to Rigel
Forbes
Rigel Pharmaceuticals Inc. said Friday it will take over development from Pfizer Inc. of a potential allergic asthma treatment that recently completed several early-stage clinical trials. The South San Francisco, Calif., development-stage company said
Rigel says Pfizer returns asthma therapy rightsReuters
Rigel Assumes Development Responsibility for Inhaled Asthma TherapyPR Newswire (press release)
Pfizer returns allergic asthma drug to RigelFierceBiotech
Xconomy
all 27 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *